CareDx, Inc. (NASDAQ:CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the award of inducement grants.
On November 5, 2026, as an inducement
AlloSure® Kidney trajectories within the first four months post-transplant were associated with three-year graft outcomes
CareDx, Inc. (NASDAQ:CDNA) — a leading precision medicine diagnostics company in transplant,
Third Quarter Revenue Growth of 39% to $139 Million
Raises 2026 Revenue Guidance to $520 Million to $530 Million and Adjusted EBITDA Guidance to $90 Million to $100 Million
CareDx, Inc. (NASDAQ:CDNA) — a leading
In an independent randomized trial, AlloSure-based monitoring demonstrates a significant reduction in kidney transplant biopsies while maintaining similar clinical outcomes
A multinational study shows AlloSure Kidney
CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the third quarter 2026 after
CareDx, Inc. (NASDAQ:CDNA) — a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced that, on July 30, 2026, CareDx granted to James McNally, the Company’s
Second Quarter Revenue Growth of 52% to $132 Million
Raises 2026 Revenue Guidance to $490 Million to $500 Million and Raises 2026 AEBITDA Guidance to $66 Million to $78 Million
CareDx, Inc. (NASDAQ:CDNA) — a
CareDx, Inc. (NASDAQ:CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after
Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung
CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine diagnostics company in transplant, specialty
NavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers
Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell
Sharpens focus on U.S. precision medicine Testing Services and Patient & Digital Solutions
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery,
Growing body of evidence supports AlloSure® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes
Data across kidney, heart, lung, and multi-organ transplantation; featuring
AlloSure® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients
Data support the role of AlloSure® Kidney as a noninvasive tool for longitudinal
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare
CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare
